Effect of XELOX regimens plus combination of endostar and thalidamide as first-line treatment for advanced colorectal cancer

中国综合临床 Pub Date : 2019-09-01 DOI:10.3760/CMA.J.ISSN.1008-6315.2019.05.012

Yuzhi Li, Y. Bao, F. Sun

{"title":"Effect of XELOX regimens plus combination of endostar and thalidamide as first-line treatment for advanced colorectal cancer","authors":"Yuzhi Li, Y. Bao, F. Sun","doi":"10.3760/CMA.J.ISSN.1008-6315.2019.05.012","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the efficacy and safety of two antiangiogenic drugs (recombinant human endostatin endostar and thalidomide) combined with capecitabine and oxaliplatin(XELOX) regimens in the treatment of advanced colorectal cancer. \n \n \nMethods \nFrom January 2015 to May 2018, 40 patients of advanced metastatic colorectal cancer with organ metastasis and non-resectable were selected from the first people′s hospital of Hefei and Anhui Provincial Hospital, and they were randomly divided into treatment and control group, with 20 cases in each group.The treatment group received intravenous infusion (IV) of endostar for continuous 7 days (day 1~7) combined with oral administration of thalidomide for continuous 14 days (day 1~14) plus XELOX regimens after the fifth dose of endostar (day 6~19), and the control group was treated with XELOX regimen (day6~19). \n \n \nResults \nThe objective response rate (ORR) was 50% (10/20) and 20% (4/20) respectively (χ2=3.956, P 0.05), and the median progression free survival (mPFS) was 6.8 in both groups.There was no significant difference in Karnofsky performance score (KPS) and incidence of adverse reactions between the two groups before and after treatment (P>0.05). \n \n \nConclusion \nCombination of endostar and thalidamide plus XELOX regimen as first-line treatment have better antitumor activity and are well-tolerated in patients with advanced colorectal cancer. \n \n \nKey words: \nRecombinant human endostatin; Endostar; Thalidomide; Advanced colorectal cancer","PeriodicalId":10365,"journal":{"name":"中国综合临床","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国综合临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6315.2019.05.012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To investigate the efficacy and safety of two antiangiogenic drugs (recombinant human endostatin endostar and thalidomide) combined with capecitabine and oxaliplatin(XELOX) regimens in the treatment of advanced colorectal cancer. Methods From January 2015 to May 2018, 40 patients of advanced metastatic colorectal cancer with organ metastasis and non-resectable were selected from the first people′s hospital of Hefei and Anhui Provincial Hospital, and they were randomly divided into treatment and control group, with 20 cases in each group.The treatment group received intravenous infusion (IV) of endostar for continuous 7 days (day 1~7) combined with oral administration of thalidomide for continuous 14 days (day 1~14) plus XELOX regimens after the fifth dose of endostar (day 6~19), and the control group was treated with XELOX regimen (day6~19). Results The objective response rate (ORR) was 50% (10/20) and 20% (4/20) respectively (χ2=3.956, P 0.05), and the median progression free survival (mPFS) was 6.8 in both groups.There was no significant difference in Karnofsky performance score (KPS) and incidence of adverse reactions between the two groups before and after treatment (P>0.05). Conclusion Combination of endostar and thalidamide plus XELOX regimen as first-line treatment have better antitumor activity and are well-tolerated in patients with advanced colorectal cancer. Key words: Recombinant human endostatin; Endostar; Thalidomide; Advanced colorectal cancer

查看原文本刊更多论文

XELOX方案联合恩妥他和沙利度胺一线治疗晚期癌症的疗效

目的探讨两种抗血管生成药物(重组人内皮抑素恩度达和沙利度胺)联合卡培他滨和奥沙利铂(XELOX)方案治疗晚期结直肠癌的疗效和安全性。方法选取2015年1月~ 2018年5月合肥市第一人民医院和安徽省省级医院的40例晚期转移性结直肠癌脏器转移不可切除患者，随机分为治疗组和对照组，每组20例。治疗组给予恩度静脉滴注(IV)，连续7天(第1~7天)，联合口服沙利度胺，连续14天(第1~14天)，在恩度第5剂(第6~19天)后加XELOX方案治疗，对照组给予XELOX方案治疗(第6~19天)。结果两组患者客观缓解率(ORR)分别为50%(10/20)和20% (4/20)(χ2=3.956, p0.05)，中位无进展生存期(mPFS)为6.8。两组患者治疗前后Karnofsky绩效评分(KPS)及不良反应发生率比较，差异均无统计学意义(P < 0.05)。结论恩度联合沙利达胺联合XELOX方案作为一线治疗对晚期结直肠癌患者具有较好的抗肿瘤活性和良好的耐受性。关键词:重组人内皮抑素;Endostar;萨力多胺;晚期结直肠癌

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中国综合临床

CiteScore

0.10

自引率

0.00%

发文量

16855

期刊介绍： Clinical Medicine of China is an academic journal organized by the Chinese Medical Association (CMA), which mainly publishes original research papers, reviews and commentaries in the field. Clinical Medicine of China is a source journal of Peking University (2000 and 2004 editions), a core journal of Chinese science and technology, an academic journal of RCCSE China Core (Extended Edition), and has been published in Chemical Abstracts of the United States (CA), Abstracts Journal of Russia (AJ), Chinese Core Journals (Selection) Database, Chinese Science and Technology Materials Directory, Wanfang Database, China Academic Journal Database, JST Japan Science and Technology Agency Database (Japanese) (2018) and other databases.